{'fraction_non_alphanumeric': 0.013485477178423237, 'fraction_numerical': 0.0, 'mean_word_length': 5.655172413793103, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Nuclear Medicine Techniques for the Detection of Active Alveolar Bone Loss

The use of bone-seeking radiopharmaceutical uptake (BSRU) as an indicator of periodontal disease activity was assessed in untreated beagles with naturally occurring periodontal disease, and in beagles treated with the non-steroidal anti-inflammatory drug, flurbiprofen. In untreated beagles, a single uptake measurement was indicative of the rate of bone loss subsequently determined by sequential radiographs. Beagles treated with flurbiprofen demonstrated a significant decrease in rate of bone loss and a corresponding decrease in BSRU. Transfer of this technology to untreated human subjects with moderate to severe periodontal disease also showed a positive correlation between a single measurement of BSRU and the rate of bone loss determined from sequential radiographs. Analysis of these data shows that a single BSRU examination may be indicative of periodontal disease activity.